INmune Bio (INMB)
Nasdaq Market Closed
INmune Bio Inc. is a clinical-stage biotechnology company developing therapies that target immune dysfunction and inflammation. The company’s work is based on the view that abnormal immune responses can drive or worsen a range of diseases, including neurodegenerative conditions, cancer-related immune suppression, and complications linked to inflammatory signalling.
Its pipeline is organised around several technology platforms. The DN-TNF platform is designed to selectively inhibit soluble tumour necrosis factor, a form of TNF associated with inflammatory disease processes, while aiming to preserve aspects of immune function linked to transmembrane TNF. XPro, also known as XPro1595, is the company’s lead programme from this platform and is being evaluated for diseases in which inflammation may contribute to progression, including neurodegenerative disorders.
INmune Bio is also developing INKmune through its Natural Killer Cell Priming Platform. This programme is intended to train or activate a patient’s natural killer cells so they may better recognise and attack cancer cells. In addition, the company has described CORDStrom as a platform involving stromal cells derived from umbilical cord tissue, with potential applications in immune and inflammatory conditions.
The company does not operate like a commercial pharmaceutical manufacturer with a broad marketed portfolio. Instead, its value is closely tied to clinical trial execution, regulatory progress, intellectual property, and the scientific validity of its immune-modulation approach. INmune Bio stands out for focusing on the intersection of innate immunity, inflammation, and disease biology, rather than pursuing a single therapeutic area or conventional small-molecule strategy.
Last updated
- Market Cap
- 35.89M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 14.53M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL, 33432
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
Inmune Bio re-elects directors, ratifies auditor - Investing.com
Zura Bio initiates exchange offer for warrants By Investing.com - Investing.com
INmune Bio Inc. to Join Russell 3000® Index
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 35.89M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 14.53M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.83
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -0.55
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -1.56
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -20.2M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -211.99%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -161.13%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.24
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.24
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 3.96
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 428.6K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1.35
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | 0 | — | — | 50K |
| Gross profit | — | 0 | — | — | 50K |
| Operating income | -5.81M | -5.47M | -7.43M | -24.57M | -9.91M |
| EBITDA | -5.76M | -5.42M | -7.41M | -8.06M | -9.91M |
| Net income | -5.41M | -5.26M | -6.47M | -24.46M | -9.74M |
| Basic EPS | -0.2 | -0.18 | -0.24 | -1.05 | -0.43 |
| Diluted EPS | -0.2 | -0.18 | -0.24 | -1.05 | -0.43 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 25.82M | 32.35M | 33.36M | 37.68M | 37.8M |
| Total liabilities | 6.19M | 8.83M | 7.98M | 8.82M | 8.13M |
| Total equity | 19.62M | 23.52M | 25.38M | 28.87M | 29.67M |
| Cash & equivalents | 21.36M | 24.75M | 27.73M | 33.37M | 19.34M |
| Current assets | 22.82M | 29.89M | 30.67M | 36.03M | 20.96M |
| Current liabilities | 5.39M | 8.42M | 7.36M | 8.59M | 7.93M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -3.4M | -2.94M | -5.44M | -7.38M | -6.82M |
| Investing cash flow | — | -143K | -193K | -706K | — |
| Financing cash flow | — | 67K | 0 | 22.27M | 5.27M |
| Change in cash | -3.39M | -2.98M | -5.64M | 14.04M | -1.59M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Inmune Bio, Inc. | View Filing | |
| edgar index | 10-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-A12B/A — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — Ganjei James Kelly | View Filing | |
| form 4 | Form 4 — Juda Scott | View Filing | |
| form 4 | Form 4 — Schroeder Timothy j | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Lowdell Mark William | View Filing | |
| form 4 | Form 4 — Moss David J | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 8-K — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| edgar index | 4 — Inmune Bio, Inc. | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — ALLEN MARCIA | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing | |
| form 4 | Form 4 — Ellspermann Cory Randall | View Filing |